Roby Zomer of MGC Pharma: CannEpil® by Named Patient Request in UK marks a momentous breakthrough
Episode 1322, Apr 12, 2023, 11:07 AM
Roby Zomer, Managing Director & CEO & Rob Clements, Chief Commercial Officer of MGC Pharmaceuticals #MXC explains how the availability of CannEpil® by Named Patient Request in the UK marks a momentous breakthrough for the company.
Highlights
· CannEpil®, MGC Pharma's Investigational Medicinal Product ("IMP") is now available in the United Kingdom by Named Patient Request to be prescribed by doctors on The General Medical Council ("GMC") specialist register across the UK.
· The products will be supplied in order to meet the needs of an individual patients where an unmet medical need exists.
· The availability via Named Patient Request follows the announcement that MGC Pharma is providing CannEpil® to an observational trial supported by the I am Billy Foundation.
· CannEpil® is in the process of a clinical development programme for patients suffering from Refractory (or Drug-Resistant) Epilepsy.
To read the full RNS click here
Highlights
· CannEpil®, MGC Pharma's Investigational Medicinal Product ("IMP") is now available in the United Kingdom by Named Patient Request to be prescribed by doctors on The General Medical Council ("GMC") specialist register across the UK.
· The products will be supplied in order to meet the needs of an individual patients where an unmet medical need exists.
· The availability via Named Patient Request follows the announcement that MGC Pharma is providing CannEpil® to an observational trial supported by the I am Billy Foundation.
· CannEpil® is in the process of a clinical development programme for patients suffering from Refractory (or Drug-Resistant) Epilepsy.
To read the full RNS click here